New study confirms that photodisinfection is rapidly effective against SARS-CoV-2 Vancouver, British Columbia, Canada - April 5, 2022 Ondine Biomedical (AIM: OBI) announces that independent research has confirmed previous results showing that Ondine Biomedical’s photodisinfection technology is highly effective against human clinical isolates of SARS-CoV-2. [...]

Ondine Biomedical treats first patients in nasal photodisinfection US Phase 2 trial for the prevention of post-operative infections Vancouver, British Columbia, Canada - February 7, 2022 Post-operative infections occur in up to 300,000 patients per year in the United States and cost the US healthcare [...]